Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DKX1U6
|
|||
Drug Name |
AMG 340
|
|||
Drug Type |
Bispecific T-cell engager
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 1 | [1] | |
Company |
Amgen
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glutamate carboxypeptidase II (GCPII) | Target Info | . | [1] |
T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [1] | |
KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
Metabolic pathways | ||||
Vitamin digestion and absorption | ||||
NetPath Pathway | TCR Signaling Pathway | |||
TNFalpha Signaling Pathway | ||||
Reactome | Amino acid synthesis and interconversion (transamination) | |||
WikiPathways | One Carbon Metabolism |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04740034) A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AMG 340, a Bispecific Antibody Targeting PSMA in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma. U.S.National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.